June 2019- Volume 15, Issue 6
In this Issue
Discovery
Duo ‘AIMS’ at AI-powered discovery efforts
Duo ‘AIMS’ at AI-powered discovery efforts
Atomwise AI platform narrows the field in drug discovery
AI gains traction
AI gains traction
Three companies kick off the second quarter with AI-based announcements
A new roadmap
A new roadmap
Scripps publishes new study on neurons and neural conditioning
A model for heart valve disease drug discovery
A model for heart valve disease drug discovery
New physiological tool featured in published paper in Experimental Biology and Medicine
Alnylam and Regeneron join on RNAi therapeutics
Alnylam and Regeneron join on RNAi therapeutics
Companies focus on ocular and CNS, and advance select programs with targets expressed in the liver
Clinical Trials
A sight for sore eyes
A sight for sore eyes
GenSight reports marked visual improvement in Phase 3 study of rare eye disease
Pneumococcal vaccine seems on track for Phase 3
Pneumococcal vaccine seems on track for Phase 3
Merck shares data about increased immune response from V114 in Phase 2 trials
Attacking Alzheimer's disease via amyloids
Attacking Alzheimer's disease via amyloids
Consortium studies Eisai drug candidates BAN2401 and elenbecestat
New Spinraza data
New Spinraza data
Biogen presents data affirming longer-term safety and durability of Spinraza (nusinersen) treatment
Contract Services
Charles River invests in Resero Analytics
Charles River invests in Resero Analytics
Access to TurboToxicology expected to provide faster delivery of high-quality toxicology reports
Shooting for the stars
Shooting for the stars
Syneos Health takes top honor at inaugural ACRP All-Stars Challenge
Forward with vaccines
Forward with vaccines
WuXi Biologics signs on for long-term vaccine manufacturing contract
Diagnostics
ArcherDX attracts money and talent
ArcherDX attracts money and talent
Company looks to advance its Reveal ctDNA 20 kits and AMP-based target enrichment system
An anti-PD-1 antibody collaboration
An anti-PD-1 antibody collaboration
Arcus and Strata announce clinical development collaboration for AB122 and predictive biomarkers
A clearer risk assessment
A clearer risk assessment
Exagen’s PC4d biomarker shows promise in determining lupus patients at risk of thrombosis
A ‘breakthrough’ for Caris
A ‘breakthrough’ for Caris
MI Transcriptome companion diagnostic test receives FDA Breakthrough Device Designation
Preclinical
Epilepsy faces new foe in miRNAs
Epilepsy faces new foe in miRNAs
InteRNA and UMC Utrecht publish preclinical evidence for potential of therapeutic aimed at miR-135a
Bridging the SynGAP in autism
Bridging the SynGAP in autism
A new study finds gene repair improves memory and seizures in adult autism model
Taking it straight to the eye
Taking it straight to the eye
Vector platform delivers gene therapy to the retina
Two For One
Two For One
CytoDyn seeks to evaluate PRO 140 in breast cancer and NASH
Commentary
Two R&D cultures: Creativity and consistency
Two R&D cultures: Creativity and consistency
There is a balance that is necessary in research and development, so let's not lose sight of keeping it overall, even if many individual people (and companies and institutions) often trend more one direction or the other
Guest Commentary: The growing potential of CAR T-cell therapy
Guest Commentary: The growing potential of CAR T-cell therapy
Andrea Toell of Lonza shares how CAR T cells are transforming immuno-oncology
Research & Development
A gene association
A gene association
Mount Sinai researchers identify twenty novel gene associations with bipolar disorder
Setting the clocks ahead for cardiac cells
Setting the clocks ahead for cardiac cells
Researchers determine a method for accelerating the maturation of iPSCs into cardiomyocytes
Q BioMed speaks up for autism
Q BioMed speaks up for autism
Research shows major breakthrough with first biomarkers for pediatric nonverbal autism subgroup
Accelerating AI adoption
Accelerating AI adoption
Group tries to reduce obstacles to AI use in life sciences
Business & Government Policy
ProBioGen and Vaccitech sign license deal for tech platform
ProBioGen and Vaccitech sign license deal for tech platform
AGE1.CR allows large-scale manufacturing with higher production yields
On the cutting edge
On the cutting edge
A roundup of instrumentation, software and other tools and technology news
Targets acquired
Targets acquired
A look at a few recent M&A deals in the pharma world
Clarifying the finish line
Clarifying the finish line
FDA releases final guidance on how interchangeability will be determined for biosimilars
Q&A
Q&A: Current affairs for CAR T
Q&A: Current affairs for CAR T
Celyad details current obstacles faced by CAR T approaches, and its own efforts to address them
Editor's Focus
Editor’s focus: The gene genie is out of the bottle
Editor’s focus: The gene genie is out of the bottle
Our progress in terms of genetics and genomics research has been quick since the Human Genome Project wrapped up, and that's good, but let's also take note of some of the warning flags that might be cropping up now
Feature
IO Summit Show Preview: Boston-bound for immuno-oncology
IO Summit Show Preview: Boston-bound for immuno-oncology
Come to Boston again, or for the first time, to get the insight on immuno-oncology
Special Reports
Special Report on Cancer: Metabolic renaissance?
Special Report on Cancer: Metabolic renaissance?
Drilling to the core of life itself: Researchers go deep into the world of metabolomics to find new therapeutic possibilities with metabo-oncology
